The combination of tarlatamab and standard anti-PD-L1 therapy as first-line maintenance therapy led to “unprecedented” survival gains among patients with extensive-stage small cell lung cancer ...
– Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal Phase III IMforte study – – First and only combination therapy for the first-line maintenance ...
Fewer than half of eligible advanced ovarian cancer patients receive first-line maintenance treatment, despite available options like bevacizumab and PARP inhibitors. The study found 48.2% of patients ...
An FDA approval is setting a new benchmark for future treatment for first-line small cell lung cancer. The FDA has greenlighted Jazz Pharmaceuticals’ Zepzelca, used in combination with Roche’s ...
Tukysa may be a patient-friendly option as a first line maintenance treatment for HER2-positive breast cancer, as Dr. Erika Hamilton explained. Tukysa (tucatinib) may represent a new patient-friendly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results